Dr. Lior Shaltiel, CEO NurExone Biologic Inc.

Dr. Lior Shaltiel, CEO

NurExone Biologic Inc.
WKN: A3DNSU | ISIN: CA67059R1091 | TSXV: NRX | FSE: J90

NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has received Orphan Drug Designation from the FDA with first-in-human expected in 2025. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

Speaker Details
Speaker Details
    Register for IIF-News